SAN
DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced it is
joining the global community of patients, caregivers, families and
healthcare providers to build broader awareness of rare diseases,
including rare neuromuscular diseases, and the urgent need for more
approved treatments for many of these conditions in support of Rare
Disease Day®.
"Rare Disease Day represents an important opportunity for all of
us, including people living with rare diseases, their friends,
family and caregivers, and advocacy organizations around the world,
to spotlight the many challenges that rare diseases present in
daily living," said Sarah Boyce, President and Chief Executive
Officer at Avidity. "We remain dedicated to building broader
awareness of the devastating impact of rare, progressive
neuromuscular disorders including DMD, DM1 and FSHD as well as rare
cardiomyopathies and to hearing from the many patients and
caregivers who inform and inspire our efforts to help. Their
optimism, courage and insights fuel the work that we do every
day."
Rare Disease Day takes place on the last day of February each
year with the goal to raise awareness of the impact of rare
diseases worldwide. EURORDIS established Rare Disease Day in 2008
and coordinates with more than 70 national alliance patient
organizations each year to honor those living with rare diseases as
well as their families and caregivers. Avidity joins with members
of the global rare disease community including patients,
caregivers, clinicians, friends and family in support of Rare
Disease Day. To learn how you can get involved, visit the EURORDIS
Rare Disease Day website here: www.rarediseaseday.org.
In recognition of Rare Disease Day, Avidity is supporting a
range of activities in efforts to build broader awareness of rare
diseases including DMD, DM1 and FSHD, such as:
- Supported the EveryLife Foundation for Rare Diseases "Rare
Disease Week on Capitol Hill", that took place February 24-26, 2025 in Washington, D.C.
- Sponsoring the Jett Foundation's webinar "Thriving with
Duchenne," being held today, February 28,
2025, including a panel discussion with people impacted
by DMD who will share their experiences.
- Participating in EURORDIS "More Than You Can Imagine"
campaign, a global effort to support people living with rare
diseases and shine a spotlight on the power of resilience and
connection.
- Sharing perspectives from the Avidity team about our commitment
to the rare disease community and how we are inspired by members of
the patient and treatment communities.
"On Rare Disease Day, let us recognize the commitment and work
necessary to bring support to those impacted by rare diseases
around the world," said Luisa Leal,
Founder and CEO of the Akari Foundation. "Alone we are rare, but
the partnership among rare disease advocacy organizations,
industry, researchers, and healthcare providers makes a profound
difference in fueling innovation and providing hope to those who
are most in need. At Akari, we work to highlight the importance of
creating a world where people impacted by Duchenne muscular
dystrophy and other rare diseases have access to new and promising
treatments as well as education and support, regardless of their
culture or background. We are proud to partner with industry
leaders such as Avidity in efforts to foster awareness and unite
the global rare disease community to achieve a better, brighter
future."
About Avidity
Avidity Biosciences, Inc.'s
mission is to profoundly improve people's lives by delivering a new
class of RNA therapeutics - Antibody Oligonucleotide Conjugates
(AOCs™). Avidity is revolutionizing the field of RNA with its
proprietary AOCs, which are designed to combine the specificity of
monoclonal antibodies with the precision of oligonucleotide
therapies to address targets and diseases previously unreachable
with existing RNA therapies. Utilizing its proprietary AOC
platform, Avidity demonstrated the first-ever successful targeted
delivery of RNA into muscle and is leading the field with clinical
development programs for three rare neuromuscular diseases:
myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD)
and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also
advancing two wholly-owned precision cardiology development
candidates addressing rare genetic cardiomyopathies. In addition,
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our
AOC platform, clinical development pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and X.
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-honors-rare-disease-day-and-global-efforts-to-support-people-and-families-impacted-by-rare-neuromuscular-diseases-302388227.html
SOURCE Avidity Biosciences, Inc.
